Sarcopenia refers to the gradual loss of skeletal muscle mass and strength associated with aging
Sarcopenia refers to the gradual loss of skeletal muscle mass and strength associated with aging. Some key symptoms include reduced muscle strength, fatigue, slow walking speed and physical impairment. The condition is often underdiagnosed and limits mobility and independence in old age. Treatment involves regular resistance exercises, adequate protein intake and nutritional supplements containing protein, creatine and vitamins D & B12. Branched-chain amino acids supplements are also commonly prescribed. Regular strength training with weights has been shown to be most effective in improving muscle mass and function.
The Global Sarcopenia Treatment Market is estimated to be valued at US$ 3.47 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Sarcopenia Treatment are Yokogawa, General Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph Technologies, Honeywell International, ABB, Schneider Electric, Aspen Technology.
With rising geriatric population globally, the demand for Sarcopenia Treatment Market Size drugs and supplements is increasing. Pharmaceutical companies are investing heavily in R&D to develop more effective drugs and combination therapies. Advancements in diagnostic technologies enable early detection and intervention. Biomarkers and imaging techniques help monitor treatment response more accurately.
Market trends
Increasing collaborations between pharma companies for drug development and marketing will be a key trend. For instance, in 2021, Boston Therapeutics teamed with Beijing-based Zhong-Mo Pharmaceuticals for developing and commercializing formulations of BC-PI’s lead compound SUGARDOWN in China, Hong Kong and Macau. Another key trend is growing adoption of telehealth and remote patient monitoring approaches for geriatric patients. This improves treatment compliance and management of the condition.
Market Opportunities
Growth opportunities exist in developing novel anabolic agents for boosting muscle protein synthesis. Investments into nutritional supplements containing protein hydrolysates and collagen peptides also hold promise. Emerging markets in Asia Pacific and Latin America will provide lucrative opportunities for sarcopenia treatment players owing to rapidly aging populations. Launching affordable generic drug and supplement options can further aid market access in developing nations.
Impact of COVID-19 on Sarcopenia Treatment Market Growth
The COVID-19 pandemic has negatively impacted the growth of the sarcopenia treatment market. During the initial phase of the pandemic, strict lockdowns were imposed across various regions which limited people’s movement and restricted access to healthcare services. This led to a decline in doctor visits and delayed treatment processes for many muscle-wasting conditions including sarcopenia. The fear of contracting the virus in hospitals also discouraged older adults from seeking timely healthcare, worsening the risks of sarcopenia. However, with the ease of lockdown restrictions and resumption of normal activities, the sarcopenia treatment market has started recovering.
The pre-COVID scenario saw steady rise in sarcopenia cases worldwide owing to rapidly aging population. Various drugs and therapies were in development and trials to address this unmet need. However, research activities were disrupted due to shutdown of facilities and diversion of resources towards COVID-19 during the pandemic. This pause in new product development and launch set back the market growth temporarily. Now, companies have resumed their R&D with protocols to ensure safety. Telehealth and homecare have also picked up to continue patient monitoring and management in a safe way.
Emphasis will be on digital healthcare solutions, remote patient management, nutrition and lifestyle modification programs to boost recovery and prevent worsening of sarcopenia amid social distancing. Collaborations between industry and research institutes will help expedite pipeline products. Overall, increased awareness about sarcopenia post pandemic and addressal of current treatment gaps will drive the market in coming years, though short-term impacts may persist.
Geographical Regions with High Sarcopenia Treatment Market Value
North America currently dominates the sarcopenia treatment market in terms of value, owing to high healthcare expenditure and prevalence of sarcopenia alongside obesity and sedentary lifestyles in developed countries like United States. Europe is also a major region supported by growing elderly population and availability of wide range of approved drugs. Both these developed markets have solid reimbursement mechanisms backing uptake of high-cost therapies.
Asia Pacific is projected to experience fastest gains due to escalating geriatric demographics in China and India along with rising healthcare standards. Middle East and Latin America present untapped opportunities due to emerging economies, though awareness needs to be enhanced. Africa has low treatment rate currently but offers future potential with increasing life expectancy. Across globe, focus on preventive healthcare is translating to early diagnosis and management of sarcopenia.
Fastest Growing Region for Sarcopenia Treatment Market
Asia Pacific region is poised to witness the fastest growth in the sarcopenia treatment market during the forecast period owing to several factors. The steeply rising geriatric population, improving access to modern medicines, growing health awareness, and increasing disposable incomes are major drivers. Presence of top players is enhancing service availability. Furthermore, the economic development has prompted populace towards sedentary urban lifestyles favoring sarcopenia risk.
Nations like China and India offer huge populations and emerging markets respectively. Japan already has one of the oldest populations globally demanding better sarcopenia solutions. Southeast Asian countries are industrializing rapidly. Overall, Asia Pacific presents a large prevalence base as well as demand uptake that will catapult the regional sarcopenia treatment market ahead of others on growth curve. Collaborations with key global players and researchers can fast-track the region on innovation and care provision.
Get More Insights On Sarcopenia Treatment Market
© 2024 Crivva - Business Promotion. All rights reserved.